[ad_1]
Announced last week Drug giant, they sell European rights on Nexium and global rights, with the exception of the United States and Japan, on Vimovo to the pharmaceutical company Grünenthal.
Now they sell including rights to Alvesco, Omnaris and Zetonna. The buyer is the Swiss pharmaceutical company Covis Pharma and its price is 350 million dollars. Astrazeneca is entitled to a sales-related compensation of up to $ 21 million over a four-year period starting in 2019.
Covis Pharma currently sells all three drugs in US markets and also holds rights in markets outside the United States.
The transaction does not include any transfer of employees or facilities Astrazeneca.
[ad_2]
Source link
